IBT
VKTX icon

International Biotechnology Trust’s Viking Therapeutics VKTX Stock Holding History

International Biotechnology Trust’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-70,000
Closed -$664K – 54
2018
Q2 		$664K Hold
70,000
– – 0.26% 52
2018
Q1 		$305K Hold
70,000
– – 0.12% 63
2017
Q4 		$284K Buy
+70,000
New +$203K 0.1% 65

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

International Biotechnology Trust's VKTX Position: Q3 2018 in Review

International Biotechnology Trust sold out of Viking Therapeutics (VKTX) in Q3 2018, closing a stake of 70,000 shares — an estimated $664K sold.

International Biotechnology Trust first reported a position in VKTX in Q4 2017 and held it in 3 quarters. The position peaked at $664K in Q2 2018. 148 funds tracked by Wall St. Rank hold VKTX as of Q3 2018.

  • International Biotechnology Trust reported no remaining Viking Therapeutics position as of Q3 2018 after selling out during the quarter.
  • International Biotechnology Trust sold 70,000 Viking Therapeutics shares in Q3 2018, an estimated $664K.
  • International Biotechnology Trust first reported a position in Viking Therapeutics in Q4 2017 and held it in 3 quarters.
  • International Biotechnology Trust's Viking Therapeutics position peaked at $664K in Q2 2018.
  • 148 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2018.

Based on International Biotechnology Trust's 13F filing for Q3 2018, filed 13 Nov 2018.